Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.180
-0.270 (-7.83%)
At close: Apr 1, 2025, 4:00 PM
3.400
+0.220 (6.92%)
After-hours: Apr 1, 2025, 4:29 PM EDT
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$230,490
Profits / Employee
-$1,224,681
Market Cap
33.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATHE News
- 5 days ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Raises A$40.0 million in Placement - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy - GlobeNewsWire
- 2 months ago - Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 5 months ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire